Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
November 2018
-
Press Release
Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1] Ziextenzo is indicated… -
Press Release
Alcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and London
Alcon is the global leader in the highly attractive and growing $23 billion eye care devices market Market leading development capabilities and innovation investments Clearly defined near and… -
Story Discovery
An up-close look at cryo-electron microscopy
Scientists are using the imaging technique to see complex molecular structures in stunning detail.
-
Story From Our Labs
Reimagining protein sequencing
Three years after discussing how to reuse an old scientific measuring device, Novartis scientists are now testing this idea as part of an innovative research project.
-
Press Release
Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease
Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65… -
Press Release
Novartis rises to second place in 2018 Access to Medicine Index
Company leads the industry in access-to-medicine management thanks to long- term commitment, as well as ongoing innovation in access to healthcare Novartis moves up one position from number 3 in… -
Press Release
Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder
reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of… -
Press Release
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation Approval… -
Press Release
Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs. endocrine therapy alone[1] CHMP opinion is… -
Key Release
Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London
Basel, November 13, 2018 - Novartis today announced that Alcon has filed an initial Form 20-F registration statement with the US Securities and Exchange Commission (SEC) in relation to the previously… -
Story Discovery
Artificial intelligence decodes cancer pathology images without image gallery
Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.
-
Story Discovery
Artificial intelligence decodes cancer pathology images
Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.